Coinbase Global, Inc. vs Charles River Laboratories Intl. Inc — how do they compare? Coinbase Global, Inc. trades at $162.22 (market cap $42.55B), while Charles River Laboratories Intl. Inc trades at $231.94 (market cap $11.14B). The key difference: Coinbase Global, Inc. is far larger — about 3.8× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.
| COIN | CRL | |
|---|---|---|
Market Cap | $42.55B | $11.14B |
Sector | Technology | Health |
52-Week High | $419.78 | $233.60 |
52-Week Low | $141.09 | $145.57 |
Enterprise Value | $39.83B | $14.00B |
Signals from Pluang's Aura AI — not financial advice
COIN trades at $157.37, down 1.07% on the day, with bearish technical signals from moving averages and a neutral RSI. The company reported mixed Q1 2026 earnings, missing estimates, but maintains strong revenue growth with 2025 revenue of $7.18 billion and net income of $1.26 billion. Recent news highlights regulatory developments and a leadership transition, with the Chief Legal Officer stepping down in July 2026.
The stock presents a high-risk opportunity with Wall Street analysts maintaining a bullish consensus price target of $228.62, implying significant upside. Key risks include earnings volatility, regulatory uncertainty, and competitive pressures. Investors should weigh the company's solid cash flow generation against its elevated valuation multiples and recent earnings misses.
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →